



A Letter from the Founder

Hello Members,

As always, thank you for your support. We strive for the CCTC to continually provide you with consolidated and up-to-date information about open clinical trials for your patients.

Please let us know if you have any concerns or suggestions for website improvement, and feel free to follow us on Twitter for the latest updates: @COMET_Trials

Sincerely,
Dr. Christine Brezden-Masley

A Letter from the Project Manager

Hi everyone,
A friendly reminder to think about posting trials onto the COMET website as they open to recruitment at your center! This can help your trials to gain more exposure and potential referrals across our network of users.

As always, please feel free to share this newsletter with any colleagues who may be interested in joining the network.

Kind Regards,
Alexandra Moskalewicz

ARTICLE RECOMMENDATION

Representation of Minorities and Women in Oncology Clinical Trials: Review of the Past 14 Years

Duma N et al. J Oncol Pract. 2018 Jan; 14(1):e1-e10. doi: 10.1200/JOP.2017.025288.

ABSTRACT:

PURPOSE: Many cancer clinical trials lack appropriate representation of specific patient populations, limiting their generalizability. Therefore, we determined the representation of ethnic minorities and women in cancer clinical trials.

METHODS: Enrollment data from all therapeutic trials reported as completed in ClinicalTrials.gov from 2003 to 2016 were analyzed. We calculated enrollment fractions (EFs) for each group, defined as the number of enrollees divided by the 2013 Surveillance, Epidemiology, and End Results (SEER) database cancer prevalence.

RESULTS: Of 1,012 clinical trials, 310 (31%) reported ethnicity with a total of 55,689 enrollees. Participation varied significantly across ethnic groups. Non-Hispanic whites were more likely to be enrolled in clinical trials (EF, 1.2%) than African Americans (EF, 0.7%; $P < .001$) and Hispanics (EF, 0.4%; $P < .001$). A decrease in African American (6% v 9.2%) and Hispanic (2.6% v 3.1%) enrollment was observed when compared with historical data from 1996 to 2002. Younger patients (age younger than 65 years) were more likely to be enrolled in clinical trials than the elderly (64% v 36%; $P < .001$). Low recruitment of female patients was observed in clinical trials for melanoma (35%), lung cancer (39%), and pancreatic cancer (40%).

CONCLUSION: We observed a decrease in recruitment of minorities over the past 14 years compared with historical data. African Americans, Hispanics, and women were less likely to be enrolled in clinical trials. Future trials should take extra measures to recruit participants that adequately represent the US cancer population.

TRIALS SNAPSHOT

Trial Type	Imaging	Observational	Prevention	Radiation Therapy	Supportive Care	Surgical Therapy	Systemic Therapy	Therapeutic	Total
Any Malignancy		1		2			7		10
Breast	2	3		3	3	1	8		20
CNS				1				1	2
GI		1	1	3			13	1	19
GU	1	1		5		1	18	1	27
Gyne						1	7		8
Head&Neck				2	1	1	3	2	9
Heme		2	1				14	1	18
Lung				9			4	1	14
Melanoma							6		6
Skin							1	1	2
Sarcoma		1							1
NET							1		1
Total	3	9	2	25	4	4	82	8	137



TRIALS OF THE MONTH

Type	Acronym	Study Title	Description	Site(s)
Breast	WO40181	A Phase II, Multicenter, Randomized Study to Compare the Efficacy of Venetoclax Plus Fulvestrant Versus Fulvestrant in Women With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer Who Experienced Disease Recurrence or Progression During or After CDK4/6 Inhibitor Therapy	<ul style="list-style-type: none"> Advanced Breast Cancer Systemic Therapy 	Southlake Regional Health Centre
GU	BL13	A Randomized Phase II Trial Assessing Trimodality Therapy With/Out Adjuvant Durvalumab to Treat Patients With Muscle-Invasive Bladder Cancer	<ul style="list-style-type: none"> Bladder Cancer Systemic Therapy 	Southlake Regional Health Centre
GI	LEAP-005	A Multicenter, Open-label Phase 2 Study of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) in Previously Treated Subjects With Selected Solid Tumors *Site is enrolling in the 3rd line gastric cohort only*	<ul style="list-style-type: none"> Gastric Cancer Systemic Therapy 	Odette Cancer Centre
Heme	SPiReL	Phase 2 Study of an Immunotherapeutic Vaccine, DPX-Survivac With Low Dose Cyclophosphamide Administered With Pembrolizumab in Patients With Persistent or Recurrent/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)	<ul style="list-style-type: none"> Recurrent/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Systemic Therapy 	Odette Cancer Centre
Lung	SAVANNAH	A Phase II, Single Arm Study Assessing the Efficacy of Osimertinib in Combination with Savolitinib in Patients with EGFRm+ and MET+, Locally Advanced or Metastatic Non-Small Cell Lung Cancer who have Progressed Following Treatment with Osimertinib	<ul style="list-style-type: none"> Non-Small Cell Lung Cancer Systemic Therapy 	North York General Hospital
CNS	CE.8	A Phase III Trial of Marizomib in Combination with Standard Temozolomide-Based Radiochemotherapy versus Standard Temozolomide-Based Radiochemotherapy Alone in Patients with Newly-Diagnosed Glioblastoma	<ul style="list-style-type: none"> Glioblastoma Systemic Therapy 	London Health Sciences Centre
Skin	PODIUM 201	A Phase 2 Study of INCMGA00012 in Participants With Metastatic Merkel Cell Carcinoma	<ul style="list-style-type: none"> Merkel Cell Carcinoma Systemic Therapy 	London Health Sciences Centre






MEMBERSHIP UPDATES

137 accruing trials

292 members

30 institutions



INSTITUTIONS

Institution	Location	Trials	Members
Cambridge Memorial Hospital	Cambridge	3	3
Grand River Hospital	Kitchener	-	7
Humber River Regional Hospital	Toronto	1	5
Kingston General Hospital	Kingston	26	3
Juravinski Cancer Centre	Hamilton	1	7
Lakeridge Health Corporation	Oshawa	-	20
London Health Sciences Centre	London	79	11
Mackenzie Health Hospital	Richmond Hill	-	6
Markham Stouffville Hospital	Markham	-	4
Mount Sinai Hospital	Toronto	1	3
North York General Hospital	Toronto	3	14
Odette Cancer Centre/Sunnybrook	Toronto	50	68
Ontario Institute for Cancer Research	Toronto	-	4
Ontario Hospital	Toronto	-	1
Ottawa Hospital	Ottawa	1	3
Princess Margaret Cancer Centre	Toronto	-	27
Quinte Health Care	Belleville	-	1
Rouge Valley Health System	Ajax	-	3
Royal Victoria Regional Health Centre	Barrie	9	23
Scarborough General Hospital	Toronto	-	3
Southlake Regional Health Centre	Newmarket	8	21
St. Joseph's Healthcare	Hamilton	-	4
St. Joseph's Health Centre	Toronto	-	3
St. Michael's Hospital	Toronto	7	14
Sudbury Regional Hospital	Sudbury	-	1
Thunder Bay Regional	Thunder Bay	-	2
Toronto General Hospital	Toronto	1	3
Trillium Health Partners	Mississauga	3	18
William Osler Health Systems	Brampton	-	3
Windsor Regional Hospital	Windsor	-	2

ACKNOWLEDGEMENTS

The CCTC has been funded by unrestricted educational grants from the following supporters:



CONTACT US

Do you have any questions, feedback, suggestions? Please do not hesitate to contact us.

30 Bond Street
Toronto, ON Canada
M5B 1W8
cometrials@smh.ca